Pemigatinib for bile duct cancer with FGFR2 changes
Treatments studied
Part of Cancer clinical trials.
This trial tests a pill called pemigatinib for people with bile duct cancer that has spread and has a specific gene change (FGFR2 fusion or rearrangement). It may slow or stop tumor growth. The study is for those whose cancer has progressed after at least one prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bile duct cancer that cannot be removed by surgery or has spread (metastasized).
- Your cancer has a specific gene change called an FGFR2 fusion or rearrangement.
- Your cancer has progressed after at least one line of chemotherapy, with or without immunotherapy.
- You have tumors that can be measured on a CT or MRI scan.
- You are in generally good health, with a performance status of 0 or 1 (able to do normal activities).
- You have not taken an FGFR inhibitor drug before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, pemigatinib and durvalumab, in people with a certain type of advanced bile duct cancer that has a specific genetic change (FGFR2 fusion or rearrangement). The goal is to see if this combination can help when standard treatments have stopped working.
This study tests a combination of two medications—pemigatinib and durvalumab—for people with advanced bile duct or gallbladder cancer that has stopped responding to prior treatment and has a specific genetic change (FGFR2 fusion). The goal is to see if this combination can shrink or control the cancer better.
This study tests a combination of two drugs—pemigatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—with or without chemotherapy, for people with advanced bile duct cancer that has an FGFR2 fusion or rearrangement. The goal is to see if this combination is more effective than standard treatment, and to find better ways to treat this type of cancer.
This trial tests a combination of three drugs (pemigatinib, atezolizumab, and bevacizumab) for people with advanced bile duct cancer that has a specific genetic change called FGFR2 fusion. The goal is to see if this combination can shrink or control the cancer when standard treatments have stopped working.
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
This trial tests two targeted drugs, pemigatinib and afatinib, together for people with advanced solid tumors that have a specific FGFR genetic change. It may be an option if standard treatments have stopped working or aren't available.
Hear when a new Unresectable Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.